Proliferation and apoptosis after whole-body irradiation: longitudinal PET study in a mouse model.

Apoptosis Irradiation PET Proliferation

Journal

European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988

Informations de publication

Date de publication:
05 Oct 2023
Historique:
received: 15 06 2023
accepted: 04 09 2023
medline: 5 10 2023
pubmed: 5 10 2023
entrez: 5 10 2023
Statut: aheadofprint

Résumé

A reliable method for regional in vivo imaging of radiation-induced cellular damage would be of great importance for the detection of therapy-induced injury to healthy tissue and the choice of adequate treatment of radiation emergency patients in both civilian and military events. This study aimed to investigate in a mouse model if positron emission tomography (PET) imaging with proliferation and apoptosis markers is potentially suitable for this purpose. Four groups, including twenty mice (wild-type C57BL/6) each, were whole-body irradiated with 0 Gy, 0.5 Gy, 1 Gy, and 3 Gy and examined by PET over a six-month period at defined time points. 3'-[ The hematopoietic bone marrow showed a significantly increased [ [

Identifiants

pubmed: 37796306
doi: 10.1007/s00259-023-06430-x
pii: 10.1007/s00259-023-06430-x
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2023. The Author(s).

Références

Robbins ME, Brunso-Bechtold JK, Pfeiffer AM, et al. Imaging radiation-induced normal tissue injury. Radiat Res. 2012;177:449–66.
doi: 10.1667/RR2530.1 pubmed: 22348250 pmcid: 3733443
Tang TT, Rendon DA, Zawaski JA. Imaging radiation-induced gastrointestinal, bone marrow injury and recovery kinetics using 18F-FDG PET. PLoS ONE. 2017;12:1–13.
Fried DV, Das SK, Marks LB. Imaging radiation-induced normal tissue injury to quantify regional dose response. Semin Radiat Oncol. 2017;27:325–31.
doi: 10.1016/j.semradonc.2017.04.004 pubmed: 28865515
Lawrence YR, Werner-Wasik M, Dicker AP. Biologically conformal treatment: biomarkers and functional imaging in radiation oncology. Future Oncol. 2008;4:689–704.
Sharma N, Neumann D, Macklis R. The impact of functional imaging on radiation medicine. Radiat Oncol. 2008;3:3–25.
doi: 10.1186/1748-717X-3-25
Fliedner TM, Friesecke I, Beyrer K. Medical management of radiation accidents: manual on the acute radiation syndrome. London: British Institute of Radiology; 2001.
Wu T, Plett PA, Chua HL, et al. Immune reconstitution and thymic involution in the acute and delayed. Health Physics Society. 2020;647–58.
Heslet L, Bay C, Nepper-Christensen S. Acute radiation syndrome (ARS) - treatment of the reduced host defense. Int J Gen Med. 2012;5:105–15.
Dainiak N, Albanese J. Medical management of acute radiation syndrome. J Radiol Prot. 2022;42:1–11.
doi: 10.1088/1361-6498/ac7d18
Hartenbach M, Delker A, Hartenbach S, et al. Dose-Dependent Uptake of 3'-deoxy-3'-[18F]Fluorothymidine by the Bowel after Total-Body Irradiation. Mol Imaging Biol. 2014;16:846–53.
Dörr W. Three A’s of repopulation during fractionated irradiation of squamous epithelia: Asymmetry loss, Acceleration of stem-cell divisions and Abortive divisions. Int J Radiat Biol. 1997;72:635–43.
doi: 10.1080/095530097142780 pubmed: 9416785
Gandara R, Mahida YR, Potten CS. Regional differences in stem and transit cell proliferation and apoptosis in the terminal ileum and colon of mice after 12 Gy. Int J Radiat Oncol Biol Phys. 2012;82:521–8.
doi: 10.1016/j.ijrobp.2011.07.015
Dubois A, Walker RE. Prospects for management of gastrointestinal injury associated with the acute radiation syndrome. Gastroenterology. 1988;95:500–7.
doi: 10.1016/0016-5085(88)90512-4 pubmed: 3292340
Kelly P, Das P, Pinnix CC, et al. Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2013;85:143–9.
doi: 10.1016/j.ijrobp.2012.09.035
Dörr W, Obeyesekere MN. A mathematical model for cell density and proliferation in squamous epithelium after single-dose irradiation. Int J Radiat Biol. 2001;77:497–505.
doi: 10.1080/09553000010022391 pubmed: 11304441
Bollineni V, Kramer G, Jansma EP, et al. A systematic review on [18F] FLT-PET uptake as a measure of treatment response in cancer patients. Eur J Cancer. 2016;55:81–97.
doi: 10.1016/j.ejca.2015.11.018 pubmed: 26820682
Buck A, Herrmann K, Dechow T, et al. Molekulare Bildgebung der Proliferation mit [18F] FLT-PET. Der Nuklearmediziner. 2009;32:154–63.
doi: 10.1055/s-0028-1119385
Jouberton E, Schmitt S, Maisonial-Besset A, et al. Interest and limits of [18F] ML-10 PET imaging for early detection of response to conventional chemotherapy. Front Oncol. 2021;11:5358.
doi: 10.3389/fonc.2021.789769
Oborski MJ, Laymon CM, Lieberman FS, et al. First use of 18F-labeled ML-10 PET to assess apoptosis change in a newly diagnosed glioblastoma multiforme patient before and early after therapy. Brain Behav. 2014;4:312–5.
doi: 10.1002/brb3.217 pubmed: 24683522 pmcid: 3967545
Sun L, Zhou K, Wang W, et al. [18F] ML-10 imaging for assessment of apoptosis response of intracranial tumor early after radiosurgery by PET/CT. Contrast Media Mol Imaging. 2018;2018:9365174.
Oborski MJ, Laymon CM, Qian Y, et al. Challenges and approaches to quantitative therapy response assessment in glioblastoma multiforme using the novel apoptosis positron emission tomography tracer F-18 ML-10. Transl Oncol. 2014;7:111–9.
doi: 10.1593/tlo.13868 pubmed: 24772214 pmcid: 3998694
Allen AM, Ben-Ami M, Reshef A, et al. Assessment of response of brain metastases to radiotherapy by PET imaging of apoptosis with 18 F-ML-10. Eur J Nucl Med Mol Imaging. 2012;39:1400–8.
doi: 10.1007/s00259-012-2150-8 pubmed: 22699524
Gu B, Liu S, Sun Y, et al. Predictive value of [18 F] ML-10 PET/CT in early response evaluation of combination radiotherapy with cetuximab on nasopharyngeal carcinoma. Mol Imaging and Biol. 2019;21:538–48.
doi: 10.1007/s11307-018-1277-9
Willard-Mack CL, Elmore SA, Hall WC, et al. Nonproliferative and proliferative lesions of the rat and mouse hematolymphoid system. Toxicol Pathol. 2019;47:665–783.
doi: 10.1177/0192623319867053 pubmed: 31526133 pmcid: 6752743

Auteurs

Maria Meindl (M)

Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany. maria.meindl@med.uni-muenchen.de.

Alexandra Bläske (A)

Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.

Katja Steiger (K)

Comparative Experimental Pathology, Institute of Pathology, TU Munich, Munich, Germany.

Simon Lindner (S)

Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.

Felix Lindheimer (F)

Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.

Kirsten Lauber (K)

Department of Radiotherapy and Radiation Oncology, LMU University Hospital, LMU Munich, Munich, Germany.

Nikko Brix (N)

Department of Radiotherapy and Radiation Oncology, LMU University Hospital, LMU Munich, Munich, Germany.

Barbara von Ungern-Sternberg (B)

Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.

Rosel Oos (R)

Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.

Giovanna Palumbo (G)

Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.

Guido Böning (G)

Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.

Simone Schüle (S)

Department of Radiology, Bundeswehr Hospital, Ulm, Germany.

Matthäus Majewski (M)

Department of Urology, Bundeswehr Hospital, Ulm, Germany.

Matthias Port (M)

Bundeswehr Institute of Radiobiology, Munich, Germany.

Sibylle Ziegler (S)

Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.

Peter Bartenstein (P)

Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.

Classifications MeSH